10-K/A: Decoy Therapeutics Files Amended 10-K with Governance Details
Sentiment:
Annual Report Amendment
Decoy Therapeutics Inc. has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to include previously omitted Part III information regarding directors, executive compensation, and corporate governance.
Delay expectedThe company is filing this Amendment No. 1 on Form 10-K/A because it will not file a definitive proxy statement containing the Part III information within 120 days after the end of the fiscal year covered by the Original 10-K.
Summary
- Decoy Therapeutics Inc. is filing an amendment (10-K/A) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- This amendment is specifically to include Part III information (Items 10-14) which was initially omitted, as the company will not file a definitive proxy statement within the required timeframe.
- The filing details the company's Board of Directors, including their classes, terms, and committee memberships.
- It also outlines executive compensation for 2025 and 2024, including base salaries, stock awards, and option awards for named executive officers.
- Information on security ownership by beneficial owners, directors, and executive officers is provided as of April 30, 2026.
- Details regarding certain relationships and related transactions, as well as director independence, are also included.
- The filing confirms the company's independent registered public accounting firm, Ernst & Young LLP, and details the fees paid for audit and other services in 2024 and 2025.
- The amendment includes updated certifications from the Principal Executive Officer and Principal Financial Officer as required by Section 302 of the Sarbanes-Oxley Act.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it provides necessary transparency on governance and compensation following a merger, but it does not contain new operational or financial performance data.
Positives
- The company is proactively filing an amendment to ensure all required disclosures are made, demonstrating compliance with SEC regulations.
- The detailed information on the Board of Directors and executive compensation provides transparency for investors.
- The inclusion of director independence assessments and committee structures highlights a commitment to corporate governance.
- The company has a clawback policy in place to comply with Nasdaq listing standards and recover excess incentive-based compensation in case of financial restatements.
Negatives
- The company will not file its definitive proxy statement within the 120-day period after its fiscal year-end, necessitating this 10-K amendment.
- The filing does not contain financial statements, as they were included in the original 10-K.
Risks
- The staggered three-year terms of the Board of Directors may delay or prevent a change in management or a change in control of the Company.
- The limitation of liability and indemnification provisions in the Company's Certificate of Incorporation and Bylaws may discourage stockholders from bringing lawsuits against directors for breach of fiduciary duties and may reduce derivative litigation.
Future Outlook
The filing does not contain specific forward-looking financial guidance. However, it details the company's governance structure, executive compensation, and security ownership, which are foundational elements for future strategic decisions and investor relations.
Management Comments
- The Board of Directors believes that the composition and functioning of its Audit Committee complies with all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, and all applicable SEC rules and regulations.
- The Board of Directors believes that the composition and functioning of its Compensation Committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC and Nasdaq rules and regulations.
- The Board of Directors believes that the composition and functioning of its Nominating and Corporate Governance Committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC and Nasdaq rules and regulations.
- The Board of Directors believes that these charter provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.
Industry Context
StockSavvy.ai notes that this amended 10-K filing by Decoy Therapeutics Inc. focuses on corporate governance and executive compensation, which is common for companies undergoing significant transitions like mergers or name changes. The detailed disclosure of board structure, director independence, and compensation practices is crucial for investor confidence and regulatory compliance in the competitive biotechnology sector.
Comparison to Industry Standards
- The company's board structure with three classes and staggered terms is a common practice in the biopharmaceutical industry, designed to ensure continuity.
- The independence of a majority of the board members, as determined by Nasdaq listing rules, aligns with industry best practices for good corporate governance.
- The compensation structure for executive officers, including base salary, potential bonuses, and long-term equity, is typical for companies in the clinical-stage biotechnology space, aiming to attract and retain talent while aligning incentives with shareholder value.
- The company's adherence to Sarbanes-Oxley Act requirements for audit, compensation, and nominating/corporate governance committees is standard for publicly traded companies in the U.S.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Dr. Bruce J. McCreedy | Frederick E. Pierce | 2025-11-12 | Vacancy created by resignation in connection with the closing of the Merger. |
| Chief Executive Officer | David J. Arthur | Frederick E. Pierce | 2025-11-12 | Appointment following the closing of the Merger. |
| Principal Executive Officer (Acting CEO) | David J. Arthur | Mark J. Rosenblum | 2025-08-17 | Resignation of Mr. Arthur as CEO and appointment of Mr. Rosenblum as Acting CEO. |
| Chief Executive Officer | Mark J. Rosenblum (Acting) | Frederick E. Pierce | 2025-11-12 | Appointment following the closing of the Merger. |
| Chief Scientific Officer | N/A | Barbara Hibner, Ph.D. | 2025-11-12 | Appointment in connection with the closing of the Merger. |
| Chief Business Officer | N/A | Peter Marschel | 2025-11-12 | Appointment in connection with the closing of the Merger. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition | The Board of Directors currently consists of seven directors divided into three classes with staggered three-year terms. | Ongoing | May delay or prevent a change of management or control. |
| Director Independence | The Board has determined that specific directors (McVicar, Burleson, Hanish, Lammers, Lieber) are independent according to Nasdaq and SEC rules. Mr. Pierce (CEO) and Mr. Arthur (former CEO) are not considered independent. | As of April 30, 2026 | Ensures compliance with listing requirements and promotes objective oversight. |
| Board Leadership Structure | Dr. William K. McVicar serves as the Chair of the Board of Directors. | Ongoing | Provides clear leadership for board meetings and strategic discussions. |
| Risk Oversight | The Board of Directors, as a whole and through its committees (Audit Committee), oversees the company's risk management process. | Ongoing | Systematic approach to identifying and mitigating major risks. |
| Insider Trading Policy | Prohibits directors, officers, and employees from engaging in hedging transactions and short sales of the Company's securities. | Adopted | Aims to align interests of insiders with those of stockholders and prevent misaligned incentives. |
| Code of Ethics | A Code of Business Conduct and Ethics is in place for all employees, executive officers, and directors, with oversight by the Nominating and Corporate Governance Committee. | Adopted | Establishes ethical standards and provides a framework for decision-making. |
| Director Nomination Process | The Nominating and Corporate Governance Committee identifies, evaluates, and recommends director candidates, considering diversity and stockholder recommendations. | Ongoing | Ensures a qualified and diverse board composition aligned with company strategy. |
| Equity Compensation Plan | The 2015 Equity Incentive Plan expired; the 2020 Equity Incentive Plan was assumed in the merger; the 2026 Equity Incentive Plan was approved and registered. | 2026-02-24 (2026 Plan Approval) | Provides a framework for future equity-based compensation to incentivize employees and align with shareholder interests. |
Related Party Transactions
- The merger with Legacy Decoy involved the conversion of Legacy Decoy stock and options into Decoy Therapeutics stock and options, with co-founders, officers, and directors of Legacy Decoy receiving shares and assumed options.
- As of December 31, 2025, an officer/founder had an outstanding Demand Note of $55,555 plus accrued interest, with an agreement to exchange it for Series B Preferred Stock contingent upon the Merger closing.
- As of December 31, 2025, a family member of an officer/founder had an outstanding Demand Note of $83,333 plus accrued interest and an outstanding Promissory Note of $100,000 plus accrued interest, with an agreement to exchange the latter for Series B Preferred Stock contingent upon the Merger closing.
- During the second half of 2024 and first half of 2025, founders of Legacy Decoy loaned Legacy Decoy approximately $140,000 through non-interest bearing notes, amended to mature in November 2026.
Stakeholder Impact
- Shareholders: Increased transparency regarding board composition, executive compensation, and security ownership. The staggered board structure may impact control dynamics.
- Employees: Executive compensation details and equity award information are disclosed. The company's equity plans are designed to retain and incentivize key personnel.
- Directors: Information on compensation, independence, and committee roles is provided. Indemnification agreements offer protection.
- Management: Details on compensation, employment agreements, and severance packages are outlined.
Next Steps
- The company will continue to operate under its current board and executive leadership structure.
- Future equity awards will be managed under the newly approved 2026 Equity Incentive Plan.
- The company is expected to file its definitive proxy statement in the future, though the delay necessitated this amendment.
Key Dates
| Date | Description |
|---|---|
| 2019-07-01 | Dr. William K. McVicar served as a member of the Board of Directors since the completion of the reverse acquisition. |
| 2019-09-01 | Mark J. Rosenblum has served as the Companys Executive Vice President of Finance and Chief Financial Officer since this date. |
| 2020-01-10 | Merger Agreement dated as of this date. |
| 2020-06-01 | Jonathan Lieber has served as a member of the Board of Directors since this date. |
| 2020-07-14 | Grant date for stock options for Mark J. Rosenblum and David J. Arthur. |
| 2020-12-02 | Grant date for stock options for Mark J. Rosenblum and David J. Arthur. |
| 2022-01-01 | The evergreen share increase provision of the 2015 ESPP ended. |
| 2022-04-01 | Grant date for stock options for Frederick E. Pierce, Barbara Hibner, Ph.D., and Peter Marschel. |
| 2023-01-03 | Grant date for restricted stock units for Mark J. Rosenblum. |
| 2023-02-20 | Grant date for stock options for David J. Arthur. |
| 2024-01-01 | The evergreen share increase provision of the 2015 ESPP ended. |
| 2024-02-20 | Company entered into a Confidential Separation Agreement and General Release with David J. Arthur and a Notice of Stock Option Amendment with Mr. Arthur. |
| 2024-02-20 | Company and Mark J. Rosenblum entered into an Amendment to Executive Employment Agreement. |
| 2024-04-01 | Effective date for reduction in cash compensation payable to non-employee directors. |
| 2024-11-12 | Mr. Pierce served as an executive officer of Innovation1 Biotech, Inc. until this date. |
| 2024-12-28 | Maturity date for a Demand Note held by an officer/founder of the Company. |
| 2025-01-10 | Merger Agreement dated as of this date. |
| 2025-02-20 | Company entered into the First Amendment to the Consulting Agreement with David J. Arthur. |
| 2025-03-06 | 1-for-12 reverse stock split effected. |
| 2025-04-30 | Date as of which aggregate market value of common stock of the registrant held by non-affiliates was calculated. |
| 2025-06-30 | Date as of which aggregate market value of common stock of the registrant held by non-affiliates was calculated. |
| 2025-07-16 | Grant date for stock options for Frederick E. Pierce, Barbara Hibner, Ph.D., and Peter Marschel. |
| 2025-08-17 | David J. Arthur's service as Chief Executive Officer and principal executive officer ceased. |
| 2025-11-12 | Merger with Legacy Decoy completed; Frederick E. Pierce appointed CEO and Class II director; Dr. Bruce J. McCreedy resigned from the Board of Directors. |
| 2025-11-18 | Company entered into executive employment agreements with Mr. Pierce, Dr. Hibner and Mr. Marschel. |
| 2025-11-20 | Form 4 filed with SEC reporting Mark J. Rosenblum's direct ownership. |
| 2025-12-31 | Fiscal year end for the Annual Report on Form 10-K. |
| 2026-01-01 | The 2015 Equity Incentive Plan expired by its terms. |
| 2026-02-24 | Company's stockholders approved the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. |
| 2026-03-06 | 1-for-12 reverse stock split effected. |
| 2026-04-02 | Company filed a Registration Statement on Form S-8 with the SEC. |
| 2026-04-27 | Number of shares of common stock outstanding as of this date. |
| 2026-04-30 | Date of the Amendment No. 1 to the Annual Report on Form 10-K. |
| 2026-04-30 | Date as of which information regarding directors and executive officers is presented. |
| 2028-01-01 | Term expiration for Class I directors. |
| 2027-01-01 | Term expiration for Class III directors. |
| 2026-01-01 | Term expiration for Class II directors. |
Keywords
Decoy Therapeutics, 10-K/A, Amendment, Annual Report, Corporate Governance, Executive Compensation, Board of Directors, Director Independence, SEC Filing, Sarbanes-Oxley Act, Nasdaq
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.